North America Direct-to-Consumer Genetic Testing Market Forecast to 2030

North America Direct-to-Consumer Genetic Testing Market Forecast to 2030 – Regional Analysis – by Test Type (Ancestry Testing, Predictive Testing, Nutrigenomics Testing, Carrier Testing, and Others), Technology (Whole Genome Sequencing, Single Nucleotide Polymorphism Chips, Targeted Analysis, and Others), and Distribution Channel (Online and Offline)

Send Enquiry

$2,485$3,885

Description

The North America Direct-to-Consumer genetic testing market was valued at US$ 716.40 million in 2022 and is expected to reach US$ 3,041.12 million by 2030; it is estimated to grow at a CAGR of 19.8% from 2022 to 2030.

Growing Incidence of Genetic Disorders Fuels the North America Direct-to-Consumer Genetic Testing Market

The global burden of genetic diseases is increasing. According to an article published in 2022 by The Guardian, ~5% of the world’s population is affected by sickle cell disease, and approximately 300,000 babies are born with sickle cell anemia worldwide every year. The World Health Organization estimates that 10 in 1,000 people are affected. This means 70 to 80 million people worldwide live with one of these diseases. In 2020, the Online Mendelian Inheritance in Man (OMIM) resource listed 6,594 diseases with known molecular genetic defects, comprising 4,225 genes. This number is continuously increasing to approximately 50-60 new genetic diseases annually, as per the Orphanet and OMIM databases. The NIH Undiagnosed Diseases Program and Network and the International Rare Diseases Research Consortium are a few initiatives further accelerating the discovery rate of novel genetic diseases.

According to the CDC, 1 in 500 African Americans are diagnosed with sickle cell disease, and the autosomal recessive mutation is carried by 1 in 12 African Americans. According to the Alzheimer’s Association, by 2023, nearly 6.7 million Americans aged 65 will have Alzheimer’s-related dementia. Furthermore, the number is expected to rise to 13.8 million by 2060, with no breakthrough that either slows or cures the disease.

The incidence of genetic disorders in newborns is also increasing. According to the World Health Organization 2022 report, neural tube defects, Down syndrome, and heart defects are a few common severe congenital disabilities. According to the CDC, in the US, Down syndrome affects nearly 6,000 newborn babies yearly, one in 700 babies; and in India, every year, nearly 23,000 to 29,000 children, one in 831, have Down syndrome. According to the report titled “Neural tube defects: Different types and a brief overview of the neurulation process and its clinical implications,” published in the Journal of Family Medicine and Primary Care in 2021, more than 300,000 cases of Neural tube defects (NTDs) are recorded worldwide each year. These factors are encouraging the introduction of genetic testing for inherited diseases.

Therefore, the increasing incidence of genetic disorders worldwide boosts the Direct-to-Consumer genetic testing market growth.

North America Direct-to-Consumer Genetic Testing Market Overview

The North America Direct-to-Consumer genetic testing market is segmented into the US, Canada, and Mexico. North America accounts for a significant market share owing to the growing prevalence of genetic diseases, high spending on research and development, product approvals by the US Food and Drug Administration (FDA), and technological advances. The presence of large healthcare businesses and the growing usage of Direct-to-Consumer genetic testing would continue to offer opportunities for market growth in the region during the period 2022-2030. Further, rising support from governments to address growing concerns about genetic diseases favors the Direct-to-Consumer genetic testing market progress in North America.

North America Direct-to-Consumer Genetic Testing Market Revenue and Forecast to 2030 (US$ Million)

North America Direct-to-Consumer Genetic Testing Market Segmentation

The North America Direct-to-Consumer genetic testing market is segmented into test type, technology, distribution channel, and country.

Based on test type, the North America Direct-to-Consumer genetic testing market is segmented into ancestry testing, predictive testing, nutrigenomics testing, carrier testing, and others. The ancestry testing market segment held the largest share in 2022.

In terms of technology, the North America Direct-to-Consumer genetic testing market is categorized into whole genome sequencing, single nucleotide polymorphism chips, targeted analysis, and others. The single nucleotide polymorphism chips segment held the largest share in 2022.

Based on distribution channel, the North America Direct-to-Consumer genetic testing market is bifurcated into online and offline. The online segment held a larger share in 2022.

Based on country, the North America Direct-to-Consumer genetic testing market is segmented the US, Canada, and Mexico. The US dominated the North America Direct-to-Consumer genetic testing market in 2022.

Ancestry Genomics Inc, Color Health Inc, Helix Inc, Myriad Genetics, Inc., Living DNA Ltd, 23andMe Inc, Genetic Technologies Ltd, Gene by Gene Ltd, and Full Genomes Corp Inc are some of the leading companies operating in the North America Direct-to-Consumer genetic testing market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

Year of Publication:

At 19.8% CAGR, the North America Direct-to-Consumer Genetic Testing Market is Speculated to be Worth US$ 3,041.12 million by 2030, says The Research Team

According to The Research Team’ research, the North America Direct-to-Consumer genetic testing market was valued at US$ 716.40 in 2022 and is expected to reach US$ 3,041.12 million by 2030, registering a CAGR of 19.8% from 2022 to 2030. Growing interest in pharmacogenetics and increasing adoption of telehealth are among the critical factors attributed to the North America Direct-to-Consumer genetic testing market expansion.

The Direct-to-Consumer genetic testing market will benefit from the increasing popularity of the pharmacogenetics field. A well-known application of gene-based personalization is pharmacogenetics, where genetic variations determine the selection of drug therapy that supports a company’s growth. A comprehensive characterization of the genetic component underlying many complex diseases, traits, and drug responses has been enabled with the help of recent technological advances. This information has made genetic testing available more extensively in healthcare and can be used to assess the risk of inherited diseases and predict response to medications. Such tests can reduce drug-related adverse events, thereby increasing the effectiveness of drugs by the means of assessing the sensitivity of a person toward a particular drug. Pharmacogenetic testing is an interesting aspect for DTC companies because test results are actionable once a relevant drug is prescribed, which may be at the time of testing or many years later. Pharmacogenetic testing is one of the primary genetic testing services of DTC-GT companies. Pharmacogenetic testing reveals genetic variations associated with drug efficacy and responses. Therefore, most people are interested in finding out the function of their genome concerning their medication intake. DTC genetic testing companies such as 23andMe allow consumers to directly access their genetic information through an online service without the involvement of medical professionals.

A new model of DTC telemedicine is becoming increasingly popular. Patients select their clinical problem on a DTC company’s website or mobile phone application and submit a medical intake form online. A doctor reviews this information and may or may not contact the patient for further information. According to an article titled “Comparison of Direct-to-Consumer Telemedicine Visits With Primary Care Visits” in the American Medical Association, DTC telemedicine companies completed more than 1 million care visits using this model in the past two years and have continued to experience growth throughout the COVID-19 pandemic. While COVID-19 testing has contributed to the rapid expansion of the Direct-to-Consumer diagnostic testing (DTC) market, DTC goes far beyond COVID-19 testing. This rapid transition to a digital workflow includes every step, from sample collection to analysis and archiving final results. Therefore, owing to the revolutionary technologies growing interest in pharmacogenetics, and rising adoption of telehealth, DTC genetic testing is becoming convenient, accessible, and effective, which is expected to boost the market growth in future.

On the contrary, high cost and privacy concerns associated with Direct-to-Consumer genetic testing hamper the growth North America Direct-to-Consumer genetic testing market .

Based on test type, the North America Direct-to-Consumer genetic testing market is segmented into ancestry testing, predictive testing, nutrigenomics testing, carrier testing, and others. The ancestry testing segment held 64.2% share of the North America Direct-to-Consumer genetic testing market in 2022, amassing US$ 459.76 million. It is projected to garner US$ 1,893.21 million by 2030 to expand at 19.4% CAGR during 2022-2030.

By technology, the North America Direct-to-Consumer genetic testing market is categorized into whole genome sequencing, single nucleotide polymorphism chips, targeted analysis, and others. The single nucleotide polymorphism chips segment held 68.4% share of North America Direct-to-Consumer genetic testing market in 2022, amassing US$ 489.74 million. It is projected to garner US$ 2,138.37 million by 2030 to expand at 20.2% CAGR during 2022-2030.

Based on distribution channel, the North America Direct-to-Consumer genetic testing market is bifurcated into online and offline. The online segment held 65.5% share of North America Direct-to-Consumer genetic testing market in 2022, amassing US$ 469.49 million. It is projected to garner US$ 2,018.59 million by 2030 to expand at 20.0% CAGR during 2022-2030.

Based on country, the North America Direct-to-Consumer genetic testing market is categorized into the US, Canada, and Mexico. The US held 83.4% share of North America Direct-to-Consumer genetic testing market in 2022, amassing US$ 597.47 million. It is projected to garner US$ 2,562.01 million by 2030 to expand at 20.0% CAGR during 2022-2030.

Key players operating in the North America Direct-to-Consumer genetic testing market are Ancestry Genomics Inc, Color Health Inc, Helix Inc, Myriad Genetics, Inc., Living DNA Ltd, 23andMe Inc, Genetic Technologies Ltd, Gene by Gene Ltd, and Full Genomes Corp Inc, among others.

– In September 2023: 23andMe Holding Co. and the Sickle Cell 101, have joined forces to expand awareness of people’s sickle cell carrier status. The collaboration will include DNA testing and access to 23andMe’s Health + Ancestry Service for up to 1,000 eligible participants, and 23andMe will be providing monetary support to Sickle Cell 101 to support this effort.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America Direct-to-Consumer genetic testing market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in North America Direct-to-Consumer genetic testing market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution

TABLE OF CONTENTS


1. Introduction
1.1 The Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Direct-to-Consumer Genetic Testing Market Landscape
4.1 Overview
4.2 PEST Analysis
5. North America Direct-to-Consumer Genetic Testing Market – Key Industry Dynamics
5.1 Market Drivers
5.1.1 Growing Incidence of Genetic Disorders
5.1.2 Increasing Awareness About Potential Benefits of Genetic Testing
5.2 Market Restraints
5.2.1 High Cost and Privacy Concerns Associated With Direct-to-Consumer Genetic Testing
5.3 Market Opportunities
5.3.1 Growing Adoption of Single Nucleotide Polymorphism (SNP) Chips
5.4 Future Trends
5.4.1 Growing Interest in Pharmacogenetics and Increasing Adoption of Telehealth
5.5 Impact Analysis
6. Direct-to-Consumer Genetic Testing Market – North America Market Analysis
6.1 Overview
6.2 North America Direct-to-Consumer Genetic Testing Market Revenue (US$ Mn), 2022 – 2030
7. North America Direct-to-Consumer genetic testing market – Revenue and Forecast to 2030 – by Test Type
7.1 Overview
7.2 North America Direct-to-Consumer Genetic Testing Market Revenue Share, by Test Type 2022 & 2030 (%)
7.3 Ancestry Testing
7.3.1 Overview
7.3.2 Ancestry Testing: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Nutrigenomics Testing
7.4.1 Overview
7.4.2 Nutrigenomics Testing: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Predictive Testing
7.5.1 Overview
7.5.2 Predictive Testing: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Carrier Testing
7.6.1 Overview
7.6.2 Carrier Testing: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Direct-to-Consumer genetic testing market – Revenue and Forecast to 2030 – by Technology
8.1 Overview
8.2 North America Direct-to-Consumer Genetic Testing Market Revenue Share, by Technology 2022 & 2030 (%)
8.3 Whole Genome Sequencing
8.3.1 Overview
8.3.2 Whole Genome Sequencing: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Single Nucleotide Polymorphism Chips
8.4.1 Overview
8.4.2 Single Nucleotide Polymorphism Chips: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Targeted Analysis
8.5.1 Overview
8.5.2 Targeted Analysis: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Direct-to-Consumer genetic testing market – Revenue and Forecast to 2030 – by Distribution Channel
9.1 Overview
9.2 North America Direct-to-Consumer Genetic Testing Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
9.3 Online Platform
9.3.1 Overview
9.3.2 Online Platform: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Offline Platform
9.4.1 Overview
9.4.2 Offline Platform: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
10. North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 – Country Analysis
10.1 North America Direct-to-Consumer Genetic Testing Market, by Key Country- Revenue (2022) (US$ Mn)
10.1.1 North America Direct-to-Consumer Genetic Testing Market, by Country, 2022 & 2030 (%)
10.1.1.1 US: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (USD Million)
10.1.1.2 US: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 US: North America Direct-to-Consumer Genetic Testing Market, by Test Type, 2020-2030 (US$ Million)
10.1.1.2.2 US: North America Direct-to-Consumer Genetic Testing Market, by Technology, 2020-2030 (US$ Million)
10.1.1.2.3 US: North America Direct-to-Consumer Genetic Testing Market, by Distribution Channel, 2020-2030 (US$ Million)
10.1.1.3 Canada: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (USD Million)
10.1.1.4 Canada: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Canada: North America Direct-to-Consumer Genetic Testing Market, by Test Type, 2020-2030 (US$ Million)
10.1.1.4.2 Canada: North America Direct-to-Consumer Genetic Testing Market, by Technology, 2020-2030 (US$ Million)
10.1.1.4.3 Canada: North America Direct-to-Consumer Genetic Testing Market, by Distribution Channel, 2020-2030 (US$ Million)
10.1.1.5 Mexico: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (USD Million)
10.1.1.6 Mexico: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Mexico: North America Direct-to-Consumer Genetic Testing Market, by Test Type, 2020-2030 (US$ Million)
10.1.1.6.2 Mexico: North America Direct-to-Consumer Genetic Testing Market, by Technology, 2020-2030 (US$ Million)
10.1.1.6.3 Mexico: North America Direct-to-Consumer Genetic Testing Market, by Distribution Channel, 2020-2030 (US$ Million)
11. North America Direct-to-Consumer Genetic Testing Market-Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 Ancestry Genomics Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Color Health Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Helix Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Myriad Genetics, Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Living DNA Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 26andMe Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Genetic Technologies Ltd
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Gene By Gene Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Full Genomes Corp Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms

LIST OF TABLES

Table 1. North America Direct-to-Consumer genetic testing market Segmentation
Table 2. US: North America Direct-to-Consumer Genetic Testing Market, by Test Type – Revenue and Forecast to 2030 (US$ Million)
Table 3. US: North America Direct-to-Consumer Genetic Testing Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 4. US: North America Direct-to-Consumer Genetic Testing Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 5. Canada: North America Direct-to-Consumer Genetic Testing Market, by Test Type – Revenue and Forecast to 2030 (US$ Million)
Table 6. Canada: North America Direct-to-Consumer Genetic Testing Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 7. Canada: North America Direct-to-Consumer Genetic Testing Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 8. Mexico: North America Direct-to-Consumer Genetic Testing Market, by Test Type – Revenue and Forecast to 2030 (US$ Million)
Table 9. Mexico: North America Direct-to-Consumer Genetic Testing Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 10. Mexico: North America Direct-to-Consumer Genetic Testing Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 11. Organic Developments Done by Companies
Table 12. Inorganic Developments Done by Companies
Table 13. Glossary of Terms, North America Direct-to-Consumer Genetic Testing Market

LIST OF FIGURES

Figure 1. North America Direct-to-Consumer genetic testing market Segmentation, By Country
Figure 2. PEST Analysis
Figure 3. North America Direct-to-Consumer Genetic Testing Market: Key Industry Dynamics
Figure 4. North America Direct-to-Consumer Genetic Testing Market: Impact Analysis of Drivers and Restraints
Figure 5. North America Direct-to-Consumer Genetic Testing Market Revenue (US$ Mn), 2020 – 2030
Figure 6. North America Direct-to-Consumer Genetic Testing Market Revenue Share, by Test Type 2022 & 2030 (%)
Figure 7. Ancestry Testing: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Nutrigenomics Testing: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Predictive Testing: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Carrier Testing: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Others: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. North America Direct-to-Consumer Genetic Testing Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 13. Whole Genome Sequencing: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Single Nucleotide Polymorphism Chips: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Targeted Analysis: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Others: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. North America Direct-to-Consumer Genetic Testing Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 18. Online Platform: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Offline Platform: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. North America Direct-to-Consumer Genetic Testing Market, by Key Country – Revenue (2022) (US$ Million)
Figure 21. North America Direct-to-Consumer Genetic Testing Market, by Country, 2022 & 2030 (%)
Figure 22. US: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Canada: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Mexico: North America Direct-to-Consumer Genetic Testing Market – Revenue and Forecast to 2030 (US$ Million)

The List of Companies – North America Direct-to-Consumer Genetic Testing Market

1. Ancestry Genomics Inc
2. Color Health Inc
3. Helix Inc
4. Myriad Genetics, Inc.
5. Living DNA Ltd
6. 23andMe Inc
7. Genetic Technologies Ltd
8. Gene By Gene Ltd
9. Full Genomes Corp Inc

Reviews

There are no reviews yet.

Be the first to review “North America Direct-to-Consumer Genetic Testing Market Forecast to 2030”